Shares in Stratagene dropped to a 52-week low of $5.40 late last week, a few days after the firm posted a second-quarter loss. Despite the announcement earlier this week of a collaboration with Merck unit Rosetta Inpharmatics (see related article), Stratagene’s shares regained little ground, closing Tuesday at $5.49, down 19.7 percent for the tracking period.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers have sequenced the northern white rhinoceros to gauge whether it could be brought back from the edge of extinction, the New York Times reports.

Bavaria expands its forensic genetic analyses to include DNA phenotyping, raising discrimination concerns.

Tufts University researchers found a role for miRNA in transmitting stress between generations, the Economist reports.

In Science this week: gut microbiome influences liver cancer growth, spread; and more.